MX2021015121A - Secuencias lider. - Google Patents

Secuencias lider.

Info

Publication number
MX2021015121A
MX2021015121A MX2021015121A MX2021015121A MX2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A
Authority
MX
Mexico
Prior art keywords
pvc
payload
effector
leader sequence
needle complex
Prior art date
Application number
MX2021015121A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas R Waterfield
Joseph Healey
Alexia Hapeshi
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of MX2021015121A publication Critical patent/MX2021015121A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2021015121A 2019-06-07 2020-06-05 Secuencias lider. MX2021015121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
MX2021015121A true MX2021015121A (es) 2022-03-17

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015121A MX2021015121A (es) 2019-06-07 2020-06-05 Secuencias lider.

Country Status (12)

Country Link
US (1) US20230076614A1 (enExample)
EP (1) EP3980545A1 (enExample)
JP (2) JP7748288B2 (enExample)
KR (1) KR20220133757A (enExample)
CN (1) CN114008205A (enExample)
AU (1) AU2020288380A1 (enExample)
BR (1) BR112021024592A2 (enExample)
CA (1) CA3142462A1 (enExample)
GB (1) GB201908155D0 (enExample)
MX (1) MX2021015121A (enExample)
SG (1) SG11202113297RA (enExample)
WO (1) WO2020245611A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
AU2023297077A1 (en) 2022-06-30 2025-01-23 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2964240B1 (en) * 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
ES2954940T3 (es) * 2015-10-14 2023-11-27 BASF Agricultural Solutions Seed US LLC Gen de delta-endotoxina axmi554 y procedimientos para su utilización

Also Published As

Publication number Publication date
BR112021024592A2 (pt) 2022-01-18
KR20220133757A (ko) 2022-10-05
JP2022535283A (ja) 2022-08-05
EP3980545A1 (en) 2022-04-13
GB201908155D0 (en) 2019-07-24
JP2025114573A (ja) 2025-08-05
SG11202113297RA (en) 2021-12-30
US20230076614A1 (en) 2023-03-09
CN114008205A (zh) 2022-02-01
AU2020288380A1 (en) 2022-01-06
WO2020245611A1 (en) 2020-12-10
CA3142462A1 (en) 2020-12-10
JP7748288B2 (ja) 2025-10-02

Similar Documents

Publication Publication Date Title
MX2021015121A (es) Secuencias lider.
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
CO2022010422A2 (es) Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
CO2021017650A2 (es) Vectores víricos y uso de los mismos en terapias celulares adoptivas
AR114275A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2019015940A (es) Compuestos que comprenden un enlazador escindible y sus usos.
MX2020013579A (es) Componentes cascada y complejos cascada producidos por ingenieria.
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
CU20180121A7 (es) Receptores de antígenos quiméricos y células t
SA519410880B1 (ar) وسائل كشف عن الضوء ذات بطانة حماية وطرق متعلقة بها
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CL2020000606A1 (es) Sistema de expresión de paramyxoviridae.
CL2022000193A1 (es) Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422)
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CL2023001666A1 (es) Composiciones de los agentes de unión a antígenos de la guanilil ciclasa c (gcc) y sus métodos de uso
UY38332A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos
AR108642A1 (es) Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos
CL2024000116A1 (es) Identificación de receptores y antígenos de células t específicos de tumores comunes
BR112015023119A2 (pt) proteína de fusão, sequência de ácido nucleico, cassete de expressão, célula, método para determinar se um composto teste é um composto inibidor de bromodomínio e kit
EA202190482A1 (ru) Способ получения фармацевтического состава на основе антитела